As we begin a new decade of research in trauma and orthopaedics, we should aim to make the most of the best available data. The last decade saw a huge increase in the volume of routinely recorded healthcare data. These datasets, particularly clinical registries and large administrative databases, can be valuable sources of information but need to be understood, analysed, interpreted, and reported carefully. We have previously highlighted the importance of understanding why a dataset was established, as well as the quality of the data in order to guide the interpretation of research findings.^[@CR1],[@CR2]^ In this editorial, we aim to revisit both the importance of such data sources and the critical methodological principles that should be followed when drawing inferences from large datasets.

We recognise that big data offers the potential to answer many questions, particularly in relation to rare events and rare diseases, that cannot be answered using traditional methods.^[@CR3],[@CR4]^ It also offers an opportunity to track practice over time and examine healthcare delivery throughout big healthcare systems.^[@CR5]-[@CR12]^ There is also huge potential in linking big data sets to address questions that cannot be looked at in any other ways.^[@CR5],[@CR13]^

We have previously highlighted the dangers of misclassification bias, lumping, reliance on proxy outcomes, and overlooking both measured and unmeasured confounders.^[@CR1]^ We have also both celebrated and warned against the power of such large numbers; while alluring, they must be interpreted using sound clinical understanding. There is a risk that size of a datasets may expand at the expense of data quality,^[@CR14],[@CR15]^ which needs to be carefully understood before inferences are drawn.

We should embrace the opportunities provided by large datasets, both to guide practice and generate hypotheses. However, although inferences drawn from registry data and administrative databases will increasingly contribute to debates, they cannot replace other study designs, particularly prospective cohort studies and randomised controlled trials. The appended framework for the reporting of registry and big data studies lays out the minimum information that should be presented, both to help readers interpret study findings appropriately and to improve the reproducibility of these important studies. Transparent reporting is at least as important in this arena as it is in others, and will be mandated.

Over the past few years, we have raised our expectations around study reporting and supported the use of well-established guidelines, such as the Consolidated Standards of Reporting Trials (CONSORT), the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Strengthening and Reporting of Observational Studies in Epidemiology (STROBE) statements. We have previously suggested using the Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement for 'big data' studies. The information and guidelines recommended by Perry et al in 2014 were excellent and set a new standard that should be followed when reporting big data studies.^[@CR1]^ We suggested at the time that these should be used as an adjunct to the STROBE statement.

We now propose an expanded version that seeks to guide authors and to reassure readers. This document will further support methodological transparency and allow us to fully exploit the huge opportunities made available by large datasets. We also encourage authors to publish protocols for big data studies in our sister journal *Bone & Joint Open*, to reassure readers that any findings were not simply the result of statistical oddities from data mining, but were considered analyses based on a priori hypotheses. We do not believe that there is a conflict between our expanded recommendations and the RECORD statement, but welcome the views of our authors, readers, reviewers and other colleagues who work with big data or rely on such studies to inform their clinical practice.

###### 

Supporting Evaluation, Analysis and Reporting of routinely Collected Healthcare Data

  Section/Topic               Item No.   Checklist item
  --------------------------- ---------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Title and abstract**                 
                              1a         Identification as a healthcare registry study in the title or abstract
                              1b         Structured summary of study design, methods, results, and conclusions
                              1c         Data source including name of databases and geographic location
                              1d         Data processing undertaken including linkage and cleaning
  **Introduction**                       
  Background and objectives   2a         Scientific background and rationale for study
                              2b         Specific objectives (if exploratory) and/or hypotheses
  **Methods**                            
  Study design                3a         Description of study design including data sources used, geographic location and data linkage
                              3b         Description of the routine healthcare data utilised, data set completeness and internal QA of the registry
                              3c         Reference to study registration document or protocol if available. Approval number and date must be included
  Participants                4a         A clear statement of the inclusion criteria for participants included in the study
                              4b         Population level selection criteria including filtering based on data quality, availability and linkage
                              4c         Data source and/or queries used including codes, time frames for recruitment, exposure and outcomes
                              4d         Settings and locations where the data were collected
  Variables                   5          Extent of missing co-variable data, handling of incomplete data, and flow diagram for dataset
                              6a         Completely defined co-variables, demographic variables, justification for selection including potential confounders and missing potentially relevant data
                              6b         If using matched or comparison cohort series (e.g. propensity matching) selection and matching criteria
  Outcomes                    7          How outcomes were determined. Justification of outcome measures, including choice of follow-up duration
  Statistical methods         8a         Precisely define access to source datasets -- is this an extract?
                              8b         Methods for data processing and handling of missing data. Flow chart for data cleaning
                              8c         Methods for data linkage if appropriate, e.g. single identifier or other method of linkage Describe any QA steps for linkage
  **Results**                            
  Participant flow            9          Patients available described by text and flow diagram (required)
  Matching                    10a        Patient numbers in each cohort based on matching criteria, or other criteria (if undertaken)
                              10b        A table showing baseline demographic and clinical characteristics for each group, and QA for matching (if undertaken)
  Numbers analysed            11         For each group, number of participants (denominator) included in each analysis and what proportion of the potential registry population was included
  Outcomes and estimation     12a        Effect estimates (e.g. odds ratios) along with precision estimates (e.g. 95% CI) for each analysis
                              12b        Make clear which confounders were adjusted for and which were not. Provide data to support the choice of statistical model, e.g. explicitly test the proportional hazards assumption before reporting data from Cox regression models
  Sensitivity analysis        13         Where sensitivity analyses have been undertaken, they should be reported completely
  **Discussion**                         
  Generalisability            14         Generalisability (external validity, applicability) of the findings to individual and population settings
  Limitations                 15a        Discussion of implications of using routinely collected data not collected for this research question should be thoroughly discussed and explored. Finding should be set against pre-existing research and justification of the use of registry data as opposed to other methods.
                              15b        Study limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
  Biases                      16         Specific considerations should be given to misclassification bias, unmeasured confounders, and changing eligibility criteria over time
  Other information                      
  Registration                17         Registration number and name of study registry or source dataset
  Protocol                    18         Where the full protocol can be accessed, if available. Who and when approval was given for the analysis along with application reference number
  Funding                     19         Sources of funding and other support
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